148 filings
Page 2 of 8
8-K
647xmnbi5hj2d3f
10 Feb 23
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
4:10pm
8-K
pj0bip
13 Jan 23
Departure of Directors or Certain Officers
4:16pm
8-K
kln9r2re1ska0y1qbo
15 Dec 22
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
4:54pm
8-K
jic930iiatia
9 Nov 22
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
4:12pm
8-K
0it4o4 i21ml
15 Sep 22
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
4:37pm
8-K
ownnnu
1 Jul 22
Termination of a Material Definitive Agreement
4:43pm
8-K
iuidnl36
17 Jun 22
Amendments to Articles of Incorporation or Bylaws
8:33am
8-K
3e5y1frj7407ykk
16 May 22
Termination of a Material Definitive Agreement
4:06pm
8-K
npaopo l68
12 May 22
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
4:11pm
8-K
tvdl pxpi
4 May 22
Rezolute, Inc. Announces Closing of Registered Direct Offering
5:20pm
8-K
pxpumx9zgaun b3eekt
2 May 22
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
6:04am
8-K
jgt2ak
30 Mar 22
Rezolute Joins the Rare Disease Company Coalition
7:28am
8-K
xqgt5nzmk3iy7 xg1b
23 Mar 22
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Results to be presented in an oral presentation at a medical congress in 2Q 2022
4:03pm
8-K
v606txkgkjrsf4
22 Feb 22
Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
4:10pm
8-K
993dsrq
9 Feb 22
Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
4:10pm
8-K
8kywfc
12 Nov 21
Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
4:15pm
8-K
1ppun7r3xfepncx
19 Oct 21
Abstract for the 2021 Asrs Meeting
4:06pm
8-K
lnk5i6y
13 Oct 21
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
5:14pm
8-K
ps1i ywagu289
23 Sep 21
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
2:53pm
8-K
5leiyvz
15 Sep 21
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
5:05pm